Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology
- PMID: 35440150
- DOI: 10.1097/JU.0000000000002713
Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology
Comment on
-
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.Eur Urol. 2021 Feb;79(2):214-221. doi: 10.1016/j.eururo.2020.08.024. Epub 2020 Aug 28. Eur Urol. 2021. PMID: 32868138 Clinical Trial.
-
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.
-
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16. Nature. 2021. PMID: 34135506 Clinical Trial.
-
An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer.Nat Commun. 2021 Aug 12;12(1):4906. doi: 10.1038/s41467-021-25103-7. Nat Commun. 2021. PMID: 34385456 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
